(Q34429383)

2 August 2017

1 reference

title

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials (English)

1 reference

2 August 2017

0 references

E S Newlands

1

1 reference

2 August 2017

M F Stevens

2

1 reference

2 August 2017

S R Wedge

3

1 reference

2 August 2017

R T Wheelhouse

4

1 reference

2 August 2017

C Brock

5

1 reference

2 August 2017

1 January 1997

1 reference

2 August 2017

Cancer Treatment Reviews

1 reference

2 August 2017

23

1 reference

2 August 2017

35-61

1 reference

2 August 2017

1

1 reference

From triazines and triazenes to temozolomide.

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Alteration of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (NSC-407347)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumor imidazotetrazines. 14. Synthesis and antitumor activity of 6- and 8-substituted imidazo[5,1-d]-1,2,3,5-tetrazinones and 8-substituted pyrazolo[5,1-d]-1,2,3,5-tetrazinones

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumor imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Extension of the pre-DNA synthetic phase of the cell cycle as a consequence of DNA alkylation in Chinese hamster cells: A possible mechanism of DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

O6-methylguanine in DNA inhibits replication in vitro by human cell extracts

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Clues to the pathogenesis of familial colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Reconstitution of the DNA base excision-repair pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Possible roles of beta-elimination and delta-elimination reactions in the repair of DNA containing AP (apurinic/apyrimidinic) sites in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumour imidazotetrazines--XI: Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Role of poly(ADP-ribose) formation in DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Possible involvement of poly(ADP-ribosyl) polymerase in triggering stress-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Induction of haemoglobin synthesis in the human leukaemia cell line K562 by monomethyltriazenes and imidazotetrazinones

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumour imidazotetrazines-X. Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one (CCRG 81045; M & B 39831; NSC 362856) on DNA methylation during induction of haemoglobin synthesis in human leukaemia cell line K562

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumour imidazotetrazines--XVIII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Antitumour imidazotetrazines--XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Plasma and tissue disposition of mitozolomide in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

The role of chemotherapy in the treatment of gliomas in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Differential inactivation of mammalian and Escherichia coli O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Temozolomide reduces the metastatic potential of lewis lung carcinoma (3LL) in mice: Role of α-6 integrin phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

O6 alkylguanine-DNA alkyltransferase activity in human myeloid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Phase II evaluation of mitozolomide in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

A registration and interpolation procedure for subvoxel matching of serially acquired MR images.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2897%2990019-0

7 January 2021

10.1016/S0305-7372(97)90019-0

Identifiers

DOI

1 reference

2 August 2017

1 reference